Edition:
United Kingdom

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

9.34USD
16 Aug 2019
Change (% chg)

$0.27 (+2.98%)
Prev Close
$9.07
Open
$9.17
Day's High
$9.79
Day's Low
$9.17
Volume
146,552
Avg. Vol
145,172
52-wk High
$24.34
52-wk Low
$8.79

Latest Key Developments (Source: Significant Developments)

CytomX Therapeutics Announces Qtrly Loss Per Share $0.64
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 REVENUE $9.0 MILLION VERSUS $21.3 MILLION.Q2 REVENUE ESTIMATE $16.6 MILLION -- REFINITIV IBES DATA.AS OF JUNE 30, 2019, CYTOMX HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $349.1 MILLION.QTRLY LOSS PER SHARE $0.64.  Full Article

CytomX Therapeutics Reports Second Target Selection And Program Initiation With AbbVie
Tuesday, 9 Jul 2019 

July 9 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES SECOND TARGET SELECTION AND PROGRAM INITIATION WITH ABBVIE UNDER ONGOING, MULTI-PROGRAM STRATEGIC ONCOLOGY COLLABORATION.CYTOMX THERAPEUTICS INC - SECOND TARGET SELECTION BY ITS PARTNER ABBVIE UNDER COMPANIES' 2016 DISCOVERY COLLABORATION AND LICENSING AGREEMENT.CYTOMX THERAPEUTICS INC - TARGET SELECTION TRIGGERS A $10 MILLION PAYMENT TO CYTOMX FROM ABBVIE.CYTOMX THERAPEUTICS INC - ADVANCING A CLINICAL-STAGE ASSET, CX-2029, UNDER A GLOBAL CO-DEVELOPMENT AND LICENSING AGREEMENT.  Full Article

CytomX Therapeutics Says On May 22, Board Designated Dr. Sean Mccarthy, Co's Chairman & CEO, To Assume Responsibilities Of Principal Financial Officer
Wednesday, 29 May 2019 

May 29 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS - ON MAY 22, BOARD DESIGNATED DR. SEAN MCCARTHY, CO'S CHAIRMAN & CEO, TO ASSUME RESPONSIBILITIES OF PRINCIPAL FINANCIAL OFFICER.CYTOMX THERAPEUTICS - MCCARTHY'S APPOINTMENT FOLLOWS DEPARTURE OF DEBANJAN RAY, CO'S FORMER CFO WHOSE RESIGNATION BECAME EFFECTIVE ON MAY 15, 2019..CYTOMX THERAPEUTICS - BOARD DESIGNATED ROBIN KNIFSEND, TO ASSUME RESPONSIBILITIES OF PRINCIPAL ACCOUNTING OFFICER, EFFECTIVE IMMEDIATELY.  Full Article

Cytomx Therapeutics Announces Transition Of Chief Financial Officer
Monday, 25 Mar 2019 

March 25 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES TRANSITION OF CHIEF FINANCIAL OFFICER.CYTOMX THERAPEUTICS INC - DEBANJAN RAY, WILL BE STEPPING DOWN FROM COMPANY, EFFECTIVE MAY 15, 2019.CYTOMX THERAPEUTICS INC - RAY WILL CONTINUE TO BE AVAILABLE AS AN ADVISOR TO COMPANY AFTER HIS DEPARTURE.  Full Article

Cytomx Therapeutics Inc Files For Mixed Shelf Of Up To $250 Million
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION .  Full Article

CytomX Therapeutics Qtrly Loss Per Share $0.53
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 REVENUE $12.5 MILLION VERSUS $24.1 MILLION.Q3 REVENUE VIEW $16 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY LOSS PER SHARE $0.53.Q3 EARNINGS PER SHARE VIEW $-0.44 -- THOMSON REUTERS I/B/E/S.  Full Article

Cytomx Therapeutics Provides Operational Update
Wednesday, 7 Mar 2018 

March 7 (Reuters) - Cytomx Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE.CYTOMX THERAPEUTICS INC - COMPANY EXPECTS ITS EXISTING CAPITAL RESOURCES WILL BE SUFFICIENT TO FUND OPERATIONS INTO 2020.CYTOMX THERAPEUTICS - ON MARCH 6, CO RECEIVED NOTIFICATION OF PFIZER'S INTENT TO TERMINATE THEIR 2013 RESEARCH COLLABORATION, OPTION, LICENSE AGREEMENT.CYTOMX THERAPEUTICS INC - NONE OF PROGRAMS IN PFIZER COLLABORATION HAD ADVANCED TO CLINICAL CANDIDATE STAGE.  Full Article

Perceptive Advisors LLC Reports 5.6 Pct Passive Stake In CytomX Therapeutics As On Dec 8
Monday, 18 Dec 2017 

Dec 18 (Reuters) - CytomX Therapeutics Inc ::PERCEPTIVE ADVISORS LLC REPORTS 5.6 PERCENT PASSIVE STAKE IN CYTOMX THERAPEUTICS INC AS ON DEC 8 - SEC FILING.  Full Article

Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Cytomx Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC.CYTOMX THERAPEUTICS INC - ‍IND ACCEPTANCE RESULTS IN A $10 MILLION MILESTONE PAYMENT TO CYTOMX​.CYTOMX THERAPEUTICS INC - ‍BRISTOL-MYERS SQUIBB HAS RECEIVED ACCEPTANCE OF IND FROM U.S. FDA FOR A CTLA-4-DIRECTED PROBODY THERAPEUTIC​.  Full Article

CytomX reports Q3 loss per share $‍0.28​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - CytomX Therapeutics Inc :CytomX announces third quarter 2017 financial results and operational progress.Q3 revenue $24.1 million versus $3.5 million.Q3 revenue view $17.5 million -- Thomson Reuters I/B/E/S.CytomX Therapeutics Inc qtrly loss per share $‍0.28​.  Full Article